APA (7th ed.) Citation

JR, A., DF, W., TD, F., C, R., S, S., Y, Z., . . . RJ, H. (2010). Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. The Journal of pharmacology and experimental therapeutics, 332(1), 17. https://doi.org/10.1124/jpet.109.157909

Chicago Style (17th ed.) Citation

JR, Atack, et al. "Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-selective Drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans." The Journal of Pharmacology and Experimental Therapeutics 332, no. 1 (2010): 17. https://doi.org/10.1124/jpet.109.157909.

MLA (9th ed.) Citation

JR, Atack, et al. "Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-selective Drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans." The Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 1, 2010, p. 17, https://doi.org/10.1124/jpet.109.157909.